Navigation Links
Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
Date:5/18/2012

SAN DIEGO, May 18, 2012 /PRNewswire/ -- Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa™ (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.  Zysa is now ready for clinical use in the EU and countries that recognize the CE Mark. Ocera is in active discussions with potential partners for European sales and marketing.

"IBS-d is a condition affecting millions of people for which no new treatment has been approved in decades," stated Dr. Laurent Fischer, President and CEO of Ocera Therapeutics. "By securing a CE Marking for Zysa, we will, with the right partner, be able to offer a new option for the treatment of this disorder that adversely affects the lives of millions of people."   

Zysa is an oral adsorbent that removes substances that may potentiate gut secretion and contraction, thereby triggering symptoms of IBS. These include abdominal pain, diarrhea and bloating.  Zysa is also marketed as Kremezin™ in Asia to treat chronic kidney disease.

IBS can be extremely debilitating and is associated with economic burden in both direct medical costs and indirect social costs such as absenteeism and lost productivity, along with decreased quality of life.  It represents the most common diagnosis made by gastroenterologists.

In a phase 2 clinical study of patients fulfilling the Rome III criteria for IBS, 26.8% of patients treated with Zysa reported a 50% or more reduction in the number of days with abdominal pain from baseline, compared to only 10.2% of patients treated with placebo (p=0.029) at Week 4. At Week 8, response rates were 32.1 and 25.4% respectively (not statistically significant). Patients trea
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... following financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over ... loss for the quarter of $240,156 compared to net income ... For the nine months ended June 30, ...
(Date:8/27/2014)... Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... H. Mackaness is scheduled to make an investor presentation ... 2:55 p.m. Eastern Time on Wednesday, September 3, in New ... the investor presentation will be available in the Investors section ... About IRIDEX IRIDEX Corporation was founded in ...
(Date:8/27/2014)... CITY, Calif. , Aug. 27, 2014  AcelRx ... pharmaceutical company focused on the development and commercialization of ... pain, today announced that senior management will be participating ... presenting at the Morgan Stanley Global Healthcare Conference.  Details ... FBR Healthcare One on One Conference Date: Wednesday September ...
Breaking Medicine Technology:Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3
(Date:8/27/2014)... August 27, 2014 The Global and ... study on the current state of the Maleic Anhydride ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:8/27/2014)... IQ Formulations , a leading manufacturer of ... of the Cystic Fibrosis Foundation. For an entire month ... led by TigerFitness.com in which 5 percent of the ... to the respected nonprofit organization. , Last year, ... Isla, a young girl fighting Cystic Fibrosis. The company ...
(Date:8/27/2014)... 27, 2014 Aspirus Wausau Hospital today ... US with Buzz™ Digital O.R. at Aspirus Wausau Hospital, ... 13 new operating rooms will be Buzz, a centralized ... integrative system supports planning, navigation, imaging and communications connectivity. ... of intuitive software and hardware all controlled from the ...
(Date:8/27/2014)... August 27, 2014 SCOTT Sports ... Park, Utah’s first indoor mountain bike and BMX park. ... park-style bikes in both adult and youth sizes for the ... operated a distribution warehouse in Ogden, Utah, recently moved its ... , “We are proud to be a partner with the ...
(Date:8/27/2014)... Steven Reinberg HealthDay Reporter ... hormone used to reduce the need for blood transfusions might ... suggests. Synthetic erythropoietin (EPO), which stimulates red blood cell ... preterm birth, said lead researcher Dr. Petra Huppi, a professor ... in Switzerland. "The real test of whether EPO protects ...
Breaking Medicine News(10 mins):Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3
... WASHINGTON, DCThrough the identification of a gene,s impact on ... Center continue to make progress in understanding the ... repair of white matter, known as myelination. The study, ... of The Journal of Neuroscience , identified ...
... of the 5.3 million men and women seen in Department ... that use of cocaine is predictive of open-angle glaucoma, the ... that after adjustments for race and age, current and former ... Men with open-angle glaucoma also had significant exposures to amphetamines ...
... found that patients had little or no control over their ... care, but a new study shows that this has changed ... with health coverage that includes a high deductible and either ... their costs even after they initiated care. ...
... THURSDAY, Sept. 29 (HealthDay News) -- The bellowing of male ... researchers report. They found that the largest koalas produce ... males that they,re the biggest dudes in the neighborhood. ... few animals with a descended larynx, which makes the vocal ...
... their everyday lives and with support from partners can continue ... of the preliminary findings of a two-year research project funded ... married couples living with dementia make decisions on a daily ... over issues such as what to eat or wear, as ...
... , WEDNESDAY, Sept. 28 (HealthDay News) -- Cancer patients ... can have serious side effects and even mean the ... crucial that patients insist doctors use plain language ... associate professor of internal medicine at the University of ...
Cached Medicine News:Health News:Children's National researchers make breakthrough in understanding white matter development 2Health News:Children's National researchers make breakthrough in understanding white matter development 3Health News:Cocaine users have 45 percent increased risk of glaucoma 2Health News:Study finds consumers may have more control over health costs than previously thought 2Health News:Study finds consumers may have more control over health costs than previously thought 3Health News:Living with dementia and making decisions 2Health News:Cancer Patients Should Ask Doctors to Use Simple Terms 2
Instrument Cover for Vibratome....
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
Medicine Products: